WO2007067593A3 - Self-emulsifyng formulations of cetp inhibitors - Google Patents

Self-emulsifyng formulations of cetp inhibitors Download PDF

Info

Publication number
WO2007067593A3
WO2007067593A3 PCT/US2006/046503 US2006046503W WO2007067593A3 WO 2007067593 A3 WO2007067593 A3 WO 2007067593A3 US 2006046503 W US2006046503 W US 2006046503W WO 2007067593 A3 WO2007067593 A3 WO 2007067593A3
Authority
WO
WIPO (PCT)
Prior art keywords
formulations
emulsifyng
self
cetp inhibitors
cetp inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/046503
Other languages
French (fr)
Other versions
WO2007067593A2 (en
Inventor
Agam R Sheth
Bhagwant Rege
Soumojeet Ghosh
Laman L Alani
Craig A Mckelvey
Maria T Cruanes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Priority to EP06839075A priority Critical patent/EP1965764B1/en
Priority to AT06839075T priority patent/ATE516016T1/en
Priority to US12/085,745 priority patent/US8486983B2/en
Publication of WO2007067593A2 publication Critical patent/WO2007067593A2/en
Publication of WO2007067593A3 publication Critical patent/WO2007067593A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A liquid formulation for oral administration of the CETP inhibitor of formula (I) has improved bioavailability compared with conventional solid formulations. The formulation comprises the CETP inhibitor, or a pharmaceutically acceptable salt thereof; an oil; and one or more nonionic surfactants having a hydrophilic lipophilic balance (HLB)>10.
PCT/US2006/046503 2005-12-05 2006-12-05 Self-emulsifyng formulations of cetp inhibitors Ceased WO2007067593A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP06839075A EP1965764B1 (en) 2005-12-05 2006-12-05 Self-emulsifying formulations of cetp inhibitors
AT06839075T ATE516016T1 (en) 2005-12-05 2006-12-05 SELF-EMULSIFYING FORMULATIONS OF CETP INHIBITORS
US12/085,745 US8486983B2 (en) 2005-12-05 2006-12-05 Self-emulsifying formulations of CETP inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74245105P 2005-12-05 2005-12-05
US60/742,451 2005-12-05

Publications (2)

Publication Number Publication Date
WO2007067593A2 WO2007067593A2 (en) 2007-06-14
WO2007067593A3 true WO2007067593A3 (en) 2007-10-25

Family

ID=38123443

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/046503 Ceased WO2007067593A2 (en) 2005-12-05 2006-12-05 Self-emulsifyng formulations of cetp inhibitors

Country Status (4)

Country Link
US (1) US8486983B2 (en)
EP (1) EP1965764B1 (en)
AT (1) ATE516016T1 (en)
WO (1) WO2007067593A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7781426B2 (en) 2005-12-30 2010-08-24 Merck Sharp & Dohme Corp. CETP inhibitors
CN101378731B (en) * 2006-02-09 2014-03-05 默沙东公司 Polymer formulations of CETP inhibitors
US20100119612A1 (en) * 2007-04-17 2010-05-13 Bend Research, Inc Nanoparticles comprising non-crystalline drug
ES2569660T3 (en) 2007-06-08 2016-05-12 Mannkind Corporation IRE-1alpha inhibitors
WO2009077479A2 (en) * 2007-12-17 2009-06-25 Novartis Ag Altering high-density lipoprotein levels through carboxylesterase 1 modulation
CN102844434A (en) * 2010-04-07 2012-12-26 Isis制药公司 Modulation of cetp expression
US20120095098A1 (en) * 2010-10-18 2012-04-19 Bhiku Patel Bioavailability Enhancement Delivery System
WO2014009434A1 (en) 2012-07-11 2014-01-16 Sandoz Ag Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
EP2934518B1 (en) 2012-12-19 2020-02-19 Merck Sharp & Dohme Corp. Spirocyclic cetp inhibitors
WO2014099834A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Therapeutic thiazolidinone compounds
EP3027619B1 (en) 2013-07-30 2019-01-02 Merck Sharp & Dohme Corp. Bicyclic ureas and thiadiazolidine-1,1-dioxides as cetp inhibitors
US9688630B2 (en) 2013-10-10 2017-06-27 Merck Sharp & Dohme Corp. 3,3′-disubstituted indolines as inhibitors of cholesterol ester transfer protein
US9663534B2 (en) 2013-12-17 2017-05-30 Merck Sharp & Dohme Corp. Fused bicyclic isoxazolines as inhibitors of cholesterol ester transfer protein
EP3174537B1 (en) 2014-07-29 2021-06-23 Merck Sharp & Dohme Corp. Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein
JOP20180092A1 (en) 2017-10-13 2019-04-13 Gilead Sciences Inc Hiv protease inhibitors
TW202104210A (en) 2019-04-17 2021-02-01 美商基利科學股份有限公司 Hiv protease inhibitors
CN118948790A (en) * 2021-07-22 2024-11-15 浙江和泽医药科技股份有限公司 Abiraterone acetate soft capsule and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000295A2 (en) * 2001-06-21 2003-01-03 Pfizer Products Inc. Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
US20030072801A1 (en) * 2001-06-22 2003-04-17 Pfizer Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
WO2005011634A1 (en) * 2003-08-04 2005-02-10 Pfizer Products Inc. Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
WO2006014357A1 (en) * 2004-07-02 2006-02-09 Merck & Co., Inc. Cetp inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102003A0 (en) 1991-06-03 1992-12-30 Merck Sharp & Dohme Pharmaceutical formulation of a benzodiazepine
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
AU2006265975B2 (en) 2005-07-01 2011-12-15 Merck Sharp & Dohme Corp. Process for synthesizing a CETP inhibitor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000295A2 (en) * 2001-06-21 2003-01-03 Pfizer Products Inc. Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
US20030072801A1 (en) * 2001-06-22 2003-04-17 Pfizer Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
WO2005011634A1 (en) * 2003-08-04 2005-02-10 Pfizer Products Inc. Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
WO2006014357A1 (en) * 2004-07-02 2006-02-09 Merck & Co., Inc. Cetp inhibitors

Also Published As

Publication number Publication date
US8486983B2 (en) 2013-07-16
EP1965764A2 (en) 2008-09-10
US20090186926A1 (en) 2009-07-23
ATE516016T1 (en) 2011-07-15
WO2007067593A2 (en) 2007-06-14
EP1965764B1 (en) 2011-07-13

Similar Documents

Publication Publication Date Title
WO2006035417A3 (en) Dihydropyrimidine microcapsule - formulations
ATE516016T1 (en) SELF-EMULSIFYING FORMULATIONS OF CETP INHIBITORS
AU2002346973A1 (en) Oral Dosage Form for Propiverine or its Pharmaceutically Acceptable Salts with an Extended Release of the Active Ingredient
WO2006013369A3 (en) Compositions forming non-lamellar dispersions
IL162118A0 (en) Pharmaceutical compositions containing an orally active taxane derivative
WO2006068826A3 (en) 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
WO2003105800A3 (en) GALENIC FORM, IN THE FORM OF A FILM ADHERING TO THE MUCOSA, FOR THE ADMINISTRATION OF ACTIVE INGREDIENTS OF CANNABIS
WO2005053612A3 (en) Micellar systems useful for delivery of lipophilic or hydrophobic compounds
EP2289894A3 (en) Pyrrolo-triazine compounds useful as kinase inhibitors
WO2003002136A3 (en) Stable formulation of modified glp-1
WO2004063151A3 (en) Novel tyrosine kinase inhibitors
WO2006025070A3 (en) Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol
WO2002048148A3 (en) Pyrazolopyridine derivatives
DK2046292T3 (en) Formulations for benzimidazolylpyridyl ethers
WO2003105767A8 (en) Antifungal parenteral products
WO2006120552A3 (en) ANHYDROUS CRYSTALLINE FORMS OF N-[1-(2-ETHOXYETHYL)-5-(N-ETHYL-N-METHYLAMINO)-7-(4-METHYLPYRIDIN-2-yl-AMINO)-1H-PYRAZOLO[4,3-d]PYRIMIDINE-3-CARBONYL]METHANESULFONAMIDE
AU2002309038A1 (en) Compositions for transmucosal administration containing coenzyme Q as the active ingredient
WO2007100382A3 (en) Orally administrable gallium compositions and method of use
WO2005058890A3 (en) Hydronopol derivatives as agonists on human orl1 receptors
EP1600441A3 (en) Novel crystalline form of lercanidipin hydrochloride and processes for its preparation
WO2005007137A3 (en) Tablets containing ambroxol
WO2005034999A3 (en) Composition comprising association complex of a pharmaceutical and a poloxamer
WO2005117895A3 (en) Compositions comprising meloxicam
MY138172A (en) Pharmaceutical compositions based on azetidine derivatives

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 12085745

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006839075

Country of ref document: EP